

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**ALPINE GROUP INC**

2. Address:

660 PENNSYLVANIA AVE, SE SUITE 201, WASHINGTON, DC 20003

3. Principal place of business (if different from line 2):

4. Contact Name: ALICIA FITZPATRICK

Telephone: 2025482316

E-mail (optional): afitzpatrick@alpinegroup.com

Senate ID #: 1171-1231

House ID #: 31749083

7. Client Name:  Self

**AMGEN**

### TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: \_\_\_\_\_ 11. No Lobbying Activity:

### INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

#### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): 100,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): \_\_\_\_\_

#### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only  
 **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
 **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: ALPINE GROUP INC Client Name: AMGEN

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

Intellectual property and process patent issues S.1082, Prescription Drug User Fee Amendments of 2007

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HAWKINS, JAMES

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ALPINE GROUP INC Client Name: AMGEN

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

FDA drug safety oversight S. 1695, Biologics Price Competition and Innovation Act S.623/HR1038, Access to Life-Saving Medicines Act HR 1956, Patient Protection and Innovative Biologic Medicines Act of 2007

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BROOKS, BOB

Covered Official Position (if applicable): CHIEF OF STAFF, REP. JIM MCCRERY (R-LA)

Name: ERDEL, ANSLEY

Covered Official Position (if applicable): LEGISLATIVE ASSISTANT, REP. NATHAN DEAL (R-GA)

Name: HAWKINS, JAMES

Covered Official Position (if applicable): N/A

Name: JOHNSON, COURTNEY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ALPINE GROUP INC Client Name: AMGEN

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Medicare Coverage and Reimbursement of Erythropoiesis-Stimulating Agents

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BROOKS, BOB

Covered Official Position (if applicable): CHIEF OF STAFF, REP. JIM MCCRERY (R-LA)

Name: ERDEL, ANSLEY

Covered Official Position (if applicable): LEGISLATIVE ASSISTANT, REP. NATHAN DEAL (R-GA)

Name: HAWKINS, JAMES

Covered Official Position (if applicable): N/A

Name: JOHNSON, COURTNEY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Feb 12, 2008

Printed Name and Title: ALICIA FITZPATRICK, EXECUTIVE -

**Information Update Page:**

**Complete ONLY where registration information has changed.**

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE      Date: Feb 12, 2008

Printed Name and Title: -